AtriCure Inc (AtriCure) is a medical device company that develops, manufactures, and distributes surgical devices that help create precise lesions in cardiac and soft tissues. It offers products for atrial fibrillation (Afib) and left atrial appendage (LAA) management.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D activities include projects extending and enhancing its existing products; the developing of new devices and research into new technologies. AtriCure is advancing DEEP AF IDE pivotal study that focuses on the evaluation of the safety and efficacy of the Isolator Synergy System. The clinical trial is investigating Isolator Synergy System in a staged approach in which a minimally invasive surgical ablation procedure is performed on a patient, and then an intra-cardiac catheter procedure is performed approximately 90 to 120 days later the same patient. The company’s EPi-Sense guided coagulation system is also being evaluated under CONVERGE IDE clinical trial, with VisiTrax technology to treat symptomatically persistent Afib patients. The company has received approval for its Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction (LeAAPS) IDE clinical trial for for the prevention of ischemic stroke or systemic arterial embolism in cardiac surgery patients. It’s Hybrid Epicardial and Endocardial Sinus Node Sparing Ablation Therapy for Inappropriate Sinus Tachycardia (IST) clinical trial (HEAL-IST) received approval of symptomatic, drug refractory or drug intolerant IST. Converge Ide clinical trial to evaluate the safety and efficacy of the EPi-Sense Guided Coagulation System with VisiTrax technology to treat symptomatic persistent and long-standing persistent Afib patients. The convergent procedure, or Hybrid AF therapy, helps to provide a compelling treatment option for a large and vastly underpenetrated population of Afib patients. Its other clinical studies include cryoanalgesia study, FROST an intraoperative intercostal cryoanalgesia, and CEASE AF (hybrid ablation treatment), a non-IDE trial in Europe. It is also advancing aMAZE IDE for the treatment of persistent and long-standing persistent Afib. aMAZE clinical study focuses on evaluating the LARIAT suture delivery device for LAA closure adjunctive to pulmonary vein isolation (PVI) catheter ablation. It spent US$57.3 million on its R&D activities, which as a percentage of revenue stood at 17.4% in FY2022. The company operates a product development and R&D facility in Redwood City, California.